Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 100%High 0 · 0%

IVIg vs different infusion regimens of IVIG

Incidence of CAAs (up to 30 days) · people undergoing initial treatment for KD

Primary treatment with intravenous immunoglobulin (IVIG) probably leads to lower incidence of CAAs (up to 30 days) compared with different infusion regimens of IVIG (moderate certainty).

1 finding from 1 review

Intravenous immunoglobulin for the treatment of Kawasaki disease 2023 · Cochrane Headline outcomes only
OR 0.6 [0.4, 0.89]
8 studies · 1824 participants
Moderate

IVIg vs acetylsalicylic acid (ASA)

Incidence of CAAs (up to 30 days) · people undergoing initial treatment for KD

Primary treatment with intravenous immunoglobulin (IVIG) probably leads to lower incidence of CAAs (up to 30 days) compared with acetylsalicylic acid (ASA) (moderate certainty).

1 finding from 1 review

Intravenous immunoglobulin for the treatment of Kawasaki disease 2023 · Cochrane Headline outcomes only
OR 0.6 [0.41, 0.87]
11 studies · 1437 participants
Moderate